Female reproductive factors and risk of lymphoid neoplasm: The Japan Public Health Center-based Prospective Study

Shiori Tanaka1,2 | Norie Sawada1 | Taiki Yamaji1 | Taichi Shimazu1 | Atsushi Goto1 | Motoki Iwasaki1 | Manami Inoue1 | Shoichiro Tsugane1 | for the JPHC Study Group†

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Although a possible role of reproductive factors in lymphomagenesis has been hypothesized, results of epidemiological studies have been inconsistent. Here, we investigated the association between reproductive factors and the risk of lymphoid neoplasm and its subgroups. We used data from a large-scale, population-based prospective study in a Japanese cohort with 42,691 eligible women aged 40-69 years from 1990 to 1994. During a mean follow up of 18.7 years, we identified 176 cases of lymphoid neoplasm and 90 of non-Hodgkin lymphoma (NHL). A multivariable-adjusted Cox proportional hazards regression model was used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the risk of lymphoid neoplasms and its subgroups according to self-reported reproductive factors. Parous women had an increased risk of lymphoid neoplasm compared with nulliparous women (HR = 2.51, 95% CI, 1.03-6.13). An increased risk of lymphoid neoplasms was found in women with later onset of menarche (≤13 years old; reference: 14-15; HR = 1.75, 95% CI = 1.10-2.79; ≥16; HR = 1.93, 95% CI = 1.17-3.19; P-trend: 0.01) and a shorter menstrual cycle (28-29 days; reference: ≤27; HR = 1.60, 95% CI = 1.05-2.43, P-trend = 0.81). No association was observed between lymphoid neoplasms and other reproductive factors, including age at first birth, breastfeeding, type of menopause, or exogenous hormone use. Our study suggests that ever parity, late age at menarche and a short menstrual cycle length may be associated with the development of lymphoid neoplasms. The inconsistency seen in epidemiological research to date warrants further investigation.

KEYWORDS
epidemiology, Japan, lymphoid neoplasms, prospective cohort, reproductive factors

Abbreviations: BCL, B-cell lymphoma; BMI, body mass index; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; HR, hazard ratio; ICD-10, International Classification of Diseases, 10th Edition; JPHC Study, the Japan Public Health Center-based Prospective Study; NHL, non-Hodgkin lymphoma; PCM, plasma cell malignancy; TCL, T-cell lymphoma.

†JPHC Study Group members are listed at: http://epi.ncc.go.jp/en/jphc/781/3838.html.
Lymphoid neoplasms, a group of tumors arising from cells of the immune system, rank among the top 10 cancers by disease burden globally.1,2 One well-established risk factor for these neoplasms is severe disruption of immune function, due to conditions such as immunodeficiency disorders, infectious agents, autoimmune diseases and organ transplantation. Nevertheless, the etiology of lymphoid neoplasms remains largely unknown.2,3 Worldwide, lymphoid neoplasms are generally more common in men than women for most subtypes.2 Although the reason for this discrepancy is not clear, one possible explanation is immune-mediated associations of sex hormones with lymphomagenesis.3-5 In particular, estrogens have important immunomodulatory roles, including a biphasic effect on regulating immune responses, release of relevant cytokines, induction of B-cell differentiation, and induction of proliferation or apoptosis through hormone receptors.5-8

Previous studies have hypothesized that there is a link between lymphomagenesis and female reproductive factors through long-term and high exposure to female sex hormones.2,3 Although attention has focused on pregnancy as a protective factor against the risk of non-Hodgkin lymphoma (NHL) owing to its dramatic alternations in female sex hormones and immune response, a recent systematic review and a meta-analysis suggested only a weak or null association.3,9 Associations between the risk of NHL and late age at first birth were positive10,11 or negative,12 but most studies and a pooled analysis reported a null association.13-16 Hormones released during lactation or missed ovulations due to breastfeeding were suggested as a possible mediator of lymphomagenesis, but evidence to determine the effect of breastfeeding is scarce.10,17,18 While early age at menarche, late age at menopause and a long reproductive period are likely indicators of long exposure to female sex hormones,10,13,16,18-20 only 1 cohort study has reported a suggestive decreased risk of NHL with longer reproductive years.18 These inconsistent findings in epidemiological studies may have been due to selection bias; unclear definitions of exposure; the heterogeneity of lymphoma, given that its subtypes may have different etiology; and changes to coding system classification.

Findings from people with different reproductive patterns and incidence distribution would likely help elucidate the etiology of lymphoid neoplasms. To date, however, no evidence from Japanese populations has appeared. We hypothesized that early and/or, longer exposure to female sex hormones might reduce the risk of lymphoid neoplasms. Here, we aimed to investigate the association between reproductive factors and the risk of lymphoid neoplasms and subtypes among Japanese women.

2 | MATERIAL AND METHODS

2.1 | Study population and baseline survey

We used data from the Japan Public Health Center-based Prospective Study (JPHC study). The JPHC study enrolled 140,420 participants aged 40-69 years residing nationwide in 11 public health center areas from 1990 to 1994 (68,722 men and 71,698 women). Study participants were asked about their lifestyle, sociodemographic characteristics, personal and family medical history, diet and reproductive history using a basic questionnaire at entry. Response rate to the initial survey was 81%. Details of the study design have been described elsewhere.21 Ethical approval was obtained from the institutional review board of the National Cancer Center (approval number: 2001-021).

Of the 71,698 women, we excluded those with non-Japanese nationality (n = 20), pre-commencement emigration (n = 86), incorrect birth date (n = 5), duplicate registration (n = 4) or a late report of migration or death before the start of the follow-up period (n = 4598). Of the 66,958 eligible subjects, 59,934 women (89.5%) returned the completed questionnaire. Subjects residing in the Katsushika area (n = 4163) were excluded because of the unavailability of cancer incidence data. We further excluded those who were diagnosed with cancer before the baseline survey (n = 164) or reported a past history of any cancer at study baseline (n = 1422), leaving 54,185 women in the analyses.

2.2 | Follow up

Residency registration was used to identify participant survival or emigration. Person-years of follow up were calculated from study entry until the date of diagnosis of lymphoid neoplasm, emigration from the study area, death or the end of follow up (31 December 2013), whichever came first. Subjects from the Suita area were scheduled to be followed until December 2012. Of the eligible subjects, 31 (0.02%) were lost to follow up during the follow-up period.

2.3 | Identification of lymphoid neoplasms

Cancer cases were identified from cancer registers, and/or through active patient notification from local hospitals in the study areas. Cancers were coded according to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). Death certificates were used as an auxiliary to check the cause of death, resulting in a death-certificate-only rate of less than 1%. For patients who developed multiple primary cancers at different times, the date of earliest cancer diagnosis was used. We grouped all lymphoid neoplasm cases into NHL (9591, 9599, 9670-71, 9673, 9675, 9676, 9678, 9680, 9684, 9687, 9689, 9690-91, 9695, 9698-99, 9700, 9702, 9705, 9709, 9714, 9718-19, 9761, 9766-67, 9823, 9826), HL (9650-52, 9659, 9663), lymphoid neoplasm NOS (9590) and Plasma Cell Neoplasms (PCN) (9731-34). We further divided NHL into subgroups: the B-cell type, diffuse large B-cell neoplasms (DLBCL), follicular lymphoma (FL) and T/NK neoplasms. Adult T-cell leukemia/lymphoma (9827) (ATL) was not assessed in this study because HTLV-1 is an established cause of ATL and data on HTLV-1 was limited.22
and 1-2, 3 or ≥4 births), experience of breastfeeding (no or yes), age at first birth (≤23, 24-26 or ≥27 years), age at menarche (≤13, 14-15 or ≥16 years), exogenous hormone use (never or ever) and length of menstrual cycle (≤27, 28-29, ≥30 days or irregular). Women with a regular cycle were asked about the length of their menstrual cycle. Specific details of the frequency and duration of breastfeeding were not available. Because of the markedly low use of exogenous hormones in Japan at the time of study initiation, we did not ask for specific information on formulation, dose or duration of exogenous hormones.

As half of the study subjects were in menopausal transition during follow up, we additionally used 5-year and 10-year follow-up data for menopausal type (pre-menopause, natural menopause or surgical menopause) and age at menopause among premenopausal women in the baseline survey. Because closed-ended questions in the 5-year and 10-year surveys limited our ability to obtain a specific value for age at menopause, we conducted a predictive mean matching method to impute menopausal age, and then created a category based on the frequency distribution (≤47, 48–50 or ≥51 years). We also calculated total fertility years as the interval between menarche and imputed menopause (≤32, 33-35 or ≥36 years). Subjects who were diagnosed as having any lymphoid neoplasm before the age of menopause were verified and excluded in the analysis of age at menopause, total fertility years and menopausal type (n = 3).

2.5 Statistical analysis

We used a Cox proportional hazards regression model to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the risk of lymphoid neoplasms and subtypes according to exposure. We were not able to analyze for HL, FL, T/NK neoplasms or lymphoid neoplasms NOS because of the small numbers of these cases. We used attained age as the time scale. We included the following variables in the models as potential confounders based on prior research: study area (10); height (≤150, 151-154 or ≥155 cm); in the models as potential confounders based on prior research: (never or ever) 26; and alcohol consumption (no, occasional or regular). 27 The proportional hazards (PH) assumption was verified using Schoenfeld residuals and no variable violated the PH assumption.

We excluded those participants with missing data on age, height, smoking status, alcohol consumption, parity, age at first birth, experience of breastfeeding, age at menarche, age at menopause, menopausal status, exogenous hormone use and length of the menstrual cycle at baseline survey (n = 11 494). This left a total of 42 691 women in the primary analyses. The minimum model was built with stratification by study area to allow different baseline hazards because of the different distribution of incidence across Japan. The multivariate model was adjusted for potential confounders as mentioned above. Parity, age at menarche, menopausal status, and exogenous hormone use were included in the final model. Age at first birth and breastfeeding were additionally adjusted for when analyses were restricted to parous women. P-values for linear trends by assigning ordinal variables and the effects of unit increase of continuous variables were assessed for parity, age at first birth, age at menarche, age at menopause and total fertility years. We conducted a likelihood ratio test to compare models with and without interaction terms and to calculate a P-value for statistical interaction between all confounders and reproductive factors.

Secondary analyses were conducted using a model stratified by age group to assess the cohort effect. This is because we assumed that women born at different times may have a different distribution for reproductive history; namely, older subjects may have had a later onset of menarche and greater parity. Furthermore, because the prevalence of infectious status, such as infection with hepatitis B and C viruses, has been declining over time in Japan, 29 the risk of developing lymphoid neoplasms owing to an infectious status may differ by birth cohort. To ascertain the effect of viral infection, further analysis was conducted using a model that excluded subjects with a history of chronic hepatitis or cirrhosis (n = 415) as a possible surrogate of infectious status for hepatitis viruses. For sensitivity analysis, we included subjects who did not provide answers for all relevant variables (n = 11 494) to avoid potential selection bias arising from complete case analysis under the assumption that answers were missing at random. We performed a multiple imputation by chained equations procedure using all the variables described above as well as adding vital status and incidence of lymphoid neoplasms with 20 times’ iteration. Estimations were then combined using Rubin’s rule. Details of the imputation procedure are provided in the footnote of Table S1. All P-values reported were 2-sided, and P < .05 was set as the level of significance. All analyses were performed with STATA version 14.0 software (StataCorp LP, College Station, TX, USA).

3 RESULTS

During a mean follow up of 18.7 years for 42 691 women (801 174 person-years), a total of 176 cases of newly diagnosed lymphoid neoplasms were identified, including 61 of PCN and 90 of NHL. Subtypes of NHL were 82 of B-cell neoplasm and 49 of DLBCL. Median age at diagnosis of lymphoid neoplasm was 69 years old (interquartile: 63-75 years old).

Table 1 shows the characteristics of subjects at baseline. When we compared the distribution between women born before and after 1940, women in the older cohort (n = 22 342) reported a lower height, less smoking, less alcohol consumption, earlier age at first birth, higher rate of ever breastfeeding, later age at menarche, later age at menopause, shorter fertility span and less use of exogenous hormones. Most women in the younger cohort (n = 22 349) reported having 2 children (41.3%), versus 4 or more in the older cohort (27.5%). Similarly, the distribution of age at menarche varied by age group. Among eligible subjects, 21.2% had at least 1 missing value for relevant confounders and exposures. When we looked at female to male incidence rate ratios, women were less likely to develop lymphoid neoplasms and any type of lymphoma than men (Figure S1).

The multivariable-adjusted HR with 95% CI for the association between reproductive factors and lymphoid neoplasms and subtypes are shown in Tables 2 and 3. We found that parous women...
had an increased risk of lymphoid neoplasm compared to nulliparous women (HR = 2.51, 95% CI = 1.03-6.13). Positive associations with lymphoid neoplasm were found for later age at menarche (≤13 years old; reference: 14-15; HR = 1.75, 95% CI = 1.10-2.79; ≥16; HR = 1.93, 95% CI = 1.17-3.19; P-trend: .01) and a shorter menstrual cycle length (28-29 days; reference: ≤27; HR = 1.60, 95% CI = 1.05-2.43; ≥30; HR = 1.38, 95% CI = .96-1.96; P-trend: .81).

Regarding site-specific lymphoma, trends for increased risk of PCM were found in women with later age at menarche (P-trend: .06), later age at menopause (P-trend: .02; 1-year increase = 1.11, 95% CI = 1.02-1.21) and longer fertility years (P-trend: .02; 1-year increase = 1.10, 95% CI = 1.01-1.20). An increased risk of PCM was associated with a shorter length of menstrual cycle (28-29 days; reference: ≤27; HR = 2.05, 95% CI = 1.03-4.10). A trend towards increased risk of the B-cell type of NHL was observed in women with late age at menarche (P-trend: .04). A positive association was seen between risk of DLBCL and a shorter length of menstrual cycle (28-29 days;  

### TABLE 1 Basic characteristics of study subjects at baseline survey of the Japan Public Health Center-based Prospective Study

| Characteristic                  | Total   | ≥1940  | <1940  | P-value<sup>a</sup> |
|--------------------------------|---------|--------|--------|----------------------|
| Number of subjects (n)         | 42,691  | 22,349 | 20,342 | <.01                 |
| Age at recruitment, y<sup>b</sup> | 51.3 (8.0) | 45.0 (3.8) | 58.3 (5.1) | <.01                 |
| Height (cm)<sup>b</sup>        | 152.2 (5.6) | 153.5 (5.3) | 150.7 (5.57) | <.01                 |
| Non-smoker, %                  | 91.7    | 89.8   | 93.4   | <.01                 |
| Non-drinker, %                 | 76.2    | 68.3   | 84.0   | <.01                 |

Reproductive factors

| Parity, %                      |         |        |        |
|--------------------------------|---------|--------|--------|
| 0                              | 7.2     | 7.4    | 7.0    | <.01 |
| 1                              | 7.2     | 7.7    | 6.8    |
| 2                              | 34.7    | 41.3   | 27.5   |
| 3                              | 27.8    | 28.9   | 26.7   |
| ≥4                             | 23.6    | 14.8   | 32.9   |

| Age at first birth, y<sup>b,c</sup> | 24.9 (3.5) | 25.1 (3.4) | 24.8 (3.5) | <.01 |

| Ever breastfed, %<sup>c</sup> | 87.5 | 84.3 | 91.4 |

| Age at menarche, y, %          |         |        |        |
|--------------------------------|---------|--------|--------|
| ≤13                            | 29.3    | 43.0   | 14.2   | <.01 |
| 14-15                          | 45.4    | 48.0   | 42.5   |
| 16+                            | 25.3    | 9.0    | 43.3   |

| Age at menopause, y<sup>b,d</sup> | 48.8 (3.9) | 48.2 (3.9) | 49.3 (4.0) | <.01 |

| Total fertility years<sup>b,d</sup> | 33.3 (4.5) | 31.6 (4.8) | 33.7 (4.4) | <.01 |

| Menopausal types, %<sup>d</sup>  |         |        |        |
|--------------------------------|---------|--------|--------|
| Natural menopause              | 88.1    | 85.4   | 90.2   | <.01 |
| Surgical menopause             | 11.9    | 14.6   | 9.8    |

| Ever use of exogenous hormone, % | 12.4 | 13.7 | 11.0 | <.01 |

| Length of menstrual cycle, d<sup>b</sup> | 27.7 (5.0) | 27.7 (4.7) | 27.6 (5.4) | 0.09 |

<sup>a</sup>Analysis of variance (ANOVA) for continuous variables or the χ<sup>2</sup> test for categorical variables.

<sup>b</sup>Mean (standard deviation).

<sup>c</sup>Parous women only.

<sup>d</sup>Postmenopause using baseline, 5- and 10-y surveys.
TABLE 2 Multi-adjusted HR (95% CI) for risk of lymphoid neoplasms and plasma cell neoplasms according to reproductive factors in the JPHC Study

| Variable                  | Category    | Person-years | Lymphoid neoplasm | Plasma cell neoplasm |
|---------------------------|-------------|--------------|-------------------|----------------------|
|                           |             |              | Cases    | HR       | 95% CI   | P-trend | Cases    | HR       | 95% CI   | P-trend |
|                           |             |              | 1c       |          |          |         | 1c       |          |          |         |
| Parous                    | No          | 52 951       | 5        | 1c       | Reference|          | 1        | 1c       | Reference|          |
|                           | Yes         | 748 367      | 171      | 2.51     | 1.03-6.13| 0.78     | 4.36     | 0.60-3.15|          |         |
| Number of births*         | 1-2         | 332 950      | 69       | 1        | Reference| 0.78     | 30       | 1        | Reference| 0.54    |
|                           | 3           | 229 026      | 48       | 0.97     | 0.66-1.42|          | 15       | 0.73     | 0.38-1.38|         |
|                           | ≥4          | 186 390      | 54       | 1.08     | 0.70-1.66| 0.91     | 0.91     | 0.72-1.15|         |         |
|                           | 1-child     |              |          |          |          |         |          |          |          |         |
|                           | increase    |              |          |          |          |         |          |          |          |         |
| Age at first birth, y≥    | ≤23         | 264 385      | 62       | 1        | Reference| 0.79     | 14       | 1        | Reference| 0.22    |
|                           | 24-26       | 288 650      | 71       | 1.12     | 0.79-1.59|          | 29       | 1.85     | 0.96-3.57|         |
|                           | ≥27         | 195 331      | 38       | 0.92     | 0.60-1.41| 0.98     | 0.93-1.03| 1.01     | 0.94-1.09|         |
| Breastfeeding*             | Never       | 93 196       | 19       | 1        | Reference|          | 6        | 1        | Reference|          |
|                           | Ever        | 655 170      | 152      | 0.91     | 0.56-1.48|          | 54       | 1.26     | 0.53-2.97| 1.26     |
| Age at menarche, y         | ≤13         | 232 123      | 24       | 1        | Reference| 0.01     | 8        | 1        | Reference| 0.06    |
|                           | 14-15       | 367 092      | 85       | 1.75     | 1.10-2.79|          | 33       | 2.29     | 1.04-5.03|         |
|                           | ≥16         | 202 103      | 67       | 1.93     | 1.17-3.19| 1.02     | 0.86-1.22| 1.02     | 0.74-1.41|         |
| Age at menopause, y        | ≤47         | 210 624      | 41       | 1        | Reference| 0.34     | 9        | 1        | Reference| 0.02    |
|                           | 48-50       | 244 329      | 54       | 0.87     | 0.57-1.33|          | 17       | 1.35     | 0.58-3.20|         |
|                           | ≥51         | 248 415      | 71       | 1.16     | 0.77-1.75| 1.02     | 0.98-1.07| 1.11     | 1.02-1.21|         |
| Total fertility span, y≥   | ≤32         | 205 679      | 43       | 1        | Reference| 0.34     | 7        | 1        | Reference| 0.02    |
|                           | 33-35       | 216 156      | 58       | 1.42     | 0.94-2.14|          | 22       | 3.48     | 1.44-8.44|         |
|                           | ≥36         | 308 065      | 66       | 1.26     | 0.81-1.94| 26       | 3.35     | 1.33-8.43|         |
| Menopausal type*           | Natural     | 621 080      | 152      | 1        | Reference|          | 50       | 1        | Reference|          |
|                           | Surgical    | 82 288       | 14       | 0.80     | 0.46-1.37|          | 5        | 0.78     | 0.31-1.98|         |
| Exogenous hormone use      | Never use   | 698 099      | 161      | 1        | Reference|          | 53       | 1        | Reference|          |
|                           | Ever use    | 103 219      | 15       | 0.80     | 0.46-1.40|          | 8        | 1.28     | 0.60-2.77|         |
| Length of menstrual cycle, d| ≤27         | 138 118      | 34       | 1.60     | 1.05-2.43| 0.81     | 14       | 2.05     | 1.03-4.10| 0.87    |
|                           | 28-29       | 365 233      | 65       | 1        | Reference|          | 20       | 1        | Reference|          |
|                           | ≥30         | 211 437      | 60       | 1.38     | 0.96-1.96|          | 22       | 1.68     | 0.91-3.10|         |
|                          | Irregular   | 86 528       | 17       | 1.31     | 0.76-2.27| 5        | 1.15     | 0.42-3.12|         |
|                          | 1-d increase|             |          |          |          |          | 1.00     | 0.97-1.03| 0.99     | 0.94-1.04|         |

* Cox proportional hazards models (using attained age as time scale) stratified by public health center area and adjusted for smoking status; alcohol consumption; height; parity; age at menarche; menopausal status; and exogenous hormone use.

b P-value for linear trend across categories of variable.

c Adjustments as in footnote "a" except the parity.

d Parous women only with additional adjustment for age at first birth and breastfeeding.

* Menopausal women only.

f Subjects with an irregular cycle were excluded.

CI, confidence interval; HR, hazard ratio; JPHC, Japan Public Health Center-based Prospective Study.

Reference: ≤27; HR = 2.90, 95% CI = 1.41-5.95). Overall, no association was found between lymphoid neoplasms or any subtype and most reproductive factors, including age at first birth, breastfeeding, menopausal type and exogenous hormone use. The results of the minimal model were not substantially different from those of the final model.
| Variable                  | Category | Person-years | Non-Hodgkin lymphoma | B-cell type of NHL | DLBCL |
|---------------------------|----------|--------------|----------------------|--------------------|-------|
|                           |          |              | Cases | HR  | 95% CI | P-trend | Cases | HR  | 95% CI | P-trend | Cases | HR  | 95% CI | P-trend |
| Parous                    | No       | 52,951       | 4     | 1°  | Reference | 1°  | Reference | 2     | 1°  | Reference | 47     | 1.66 | 0.40-6.88 |
|                           | Yes      | 748,367      | 86    | 1.58 | 0.58-4.34 | 1.41 | 0.51-3.87 | 19    | 1°  | Reference | 16     | 1.16 | 0.58-2.30 |
| Number of births d       | 1-2      | 332,950      | 34    | 1.00 | Reference | 0.75 | Reference | 31    | 1°  | Reference | 19     | 1°  | Reference | 0.85 |
|                           | 3        | 229,026      | 26    | 1.04 | 0.62-1.77 | 1.09 | 0.63-1.89 | 24    | 1°  | Reference | 16     | 1.16 | 0.58-2.30 |
|                           | ≥4       | 186,390      | 26    | 1.10 | 0.60-2.04 | 1.13 | 0.58-2.17 | 23    | 1.66 | 0.40-6.88 | 12     | 0.87 | 0.36-2.08 |
|                           | 1-child increase | 1.00 | 0.84-1.20 | 1.03 | 0.86-1.24 | 1.03 | 0.86-1.24 | 0.92 | 0.71-1.18 |
| Age at first birth, y d  | ≤23      | 264,385      | 38    | 1   | Reference | 0.16 | Reference | 34    | 1°  | Reference | 18     | 1°  | Reference | 0.43 |
|                           | 24-26    | 288,650      | 31    | 0.77 | 0.47-1.26 | 0.84 | 0.50-1.39 | 30    | 0.75 | 0.41-1.39 | 21     | 1°  | Reference | 0.57-2.08 |
|                           | ≥27      | 195,331      | 17    | 0.66 | 0.36-1.22 | 0.61 | 0.32-1.18 | 14    | 1.26 | 0.65-2.43 | 8      | 0.66 | 0.27-1.58 |
| Breastfeeding d          | Never    | 93,196       | 10    | 0.80 | 0.41-1.57 | 0.70 | 0.36-1.39 | 10    | 1°  | Reference | 7      | 1°  | Reference | 0.59 |
|                           | Ever     | 655,170      | 76    | 1.51 | 0.72-3.10 | 1.47 | 0.74-2.94 | 68    | 1°  | Reference | 40     | 0.55 | 0.24-1.26 |
| Age at menarche, y       | ≤13      | 232,123      | 13    | 1   | Reference | 0.10 | Reference | 10    | 1°  | Reference | 0.04 | 7    | 1°  | Reference | 0.59 |
|                           | 14-15    | 367,092      | 42    | 1.55 | 0.82-2.93 | 1.97 | 0.97-4.00 | 40    | 1°  | Reference | 23     | 1.32 | 0.56-3.10 |
|                           | ≥16      | 202,103      | 35    | 1.79 | 0.90-3.54 | 2.20 | 1.03-4.71 | 32    | 2.00 | 1.00-4.01 | 19     | 1.29 | 0.52-3.21 |
| Age at menopause, y e    | ≤47      | 210,624      | 26    | 1   | Reference | 0.72 | Reference | 22    | 1°  | Reference | 0.91 | 14    | 1°  | Reference | 0.73 |
|                           | 48-50    | 244,329      | 28    | 0.73 | 0.41-1.27 | 0.83 | 0.45-1.50 | 26    | 0.83 | 0.45-1.50 | 18     | 0.88 | 0.42-1.85 |
|                           | ≥51      | 248,415      | 33    | 0.87 | 0.50-1.50 | 0.99 | 0.55-1.79 | 31    | 0.99 | 0.55-1.79 | 17     | 0.87 | 0.41-1.86 |
|                          | 1-y increase | 0.99 | 0.93-1.05 | 0.99 | 0.93-1.06 | 0.99 | 0.93-1.06 | 1.00 | 0.93-1.09 |
| Total fertility span, y e| ≤32      | 205,679      | 27    | 1   | Reference | 0.87 | Reference | 24    | 1°  | Reference | 0.95 | 16    | 1°  | Reference | 0.71 |
|                           | 33-35    | 216,156      | 28    | 1.08 | 0.62-1.88 | 1.16 | 0.65-2.08 | 26    | 1.16 | 0.65-2.08 | 16     | 1.06 | 0.51-2.20 |
|                           | ≥36      | 308,065      | 32    | 0.96 | 0.54-1.72 | 1.03 | 0.56-1.91 | 29    | 1.03 | 0.56-1.91 | 17     | 0.87 | 0.40-1.90 |
|                          | 1-y increase | 0.99 | 0.94-1.05 | 1.00 | 0.94-1.06 | 1.00 | 0.94-1.06 | 1.00 | 0.93-1.08 |
| Menopausal type e         | Natural  | 621,080      | 78    | 1   | Reference | 70    | 1°  | Reference | 43    | 1°  | Reference | 6      | 1.26 | 0.53-2.99 |
|                          | Surgical | 82,288       | 9     | 1.03 | 0.51-2.06 | 1.16 | 0.57-2.33 | 9     | 1.16 | 0.57-2.33 | 6      | 1.26 | 0.53-2.99 |
| Exogenous hormone use     | Never use| 698,099      | 84    | 1   | Reference | 77    | 1°  | Reference | 46    | 1°  | Reference |
When subjects were stratified by age group, P-values for interaction were insignificant for all reproductive factors and risk of lymphoid neoplasm (Table 4). However, the magnitude and direction of association for some reproductive factors differed by age group. Regarding parity, parous women had a higher risk of lymphoid neoplasm than nulliparous women in the older cohort, versus no association in the younger cohort. A positive association of late age at menarche with risk of lymphoid neoplasm was found in women of the older cohort only, whereas the association between late age at menopause and risk of lymphoid neoplasm was statistically significant in the younger cohort. Among the 415 women who reported a history of chronic hepatitis or cirrhosis, only 1 subject developed PCN during the follow-up survey. The estimation for all malignant lymphoma and PCM using a model that excluded subjects with a history of chronic hepatitis or cirrhosis did not change substantially (data not shown). Estimations using multiple imputed datasets showed similar results for the overall results, but the results for parous versus nulliparous women in the risk of lymphoid neoplasms, age at menarche, age at menopause and total fertility years in the risk of PCM became null while the association between late age at menarche and risk of NHL changed to significant (Table S1).

### DISCUSSION

In this large-scale and well-designed prospective cohort study, we observed a decreased trend in the risk of NHL associated with the overall risk of lymphoid neoplasm, and a suggestive association with the overall risk of lymphoid neoplasm. While 1 study suggested that late onset at menarche conferred an increased risk of NHL, we observed that late age at menarche was associated with risk of lymphoid neoplasms. PCM and DLBLCL was associated with risk of late age at menarche, whereas no effect of late age at menopause was found. In contrast, results showed similar results for the overall results, but the results for parous versus nulliparous women in the risk of lymphoid neoplasms, age at menarche, age at menopause and total fertility years in the risk of PCM became null while the association between late age at menarche and risk of NHL changed to significant (Table S1).


| Variable               | Category   | Women born after 1941 (n = 22 349) person-time: 421 069 | Women born before 1940 (n = 20 349) person-time: 380 249 |
|------------------------|------------|----------------------------------------------------------|----------------------------------------------------------|
|                        |            | Cases  HR  95% CI    P-trend<sup>b</sup>  P-trend<sup>b</sup>  P-interaction |
|                        |            |            |                        |                                                      |                                                      |
| Parous                 | No         | 3          | 1<sup>c</sup>  Reference  | 2          | 1<sup>c</sup>  Reference  | 0.17                                                  |
|                        | Yes        | 55         | 1.28  0.40-4.10  | 116        | 4.41  1.09-17.9  |                                                      |
| Number of births<sup>d</sup> | 1-2       | 27         | 1  Reference  | 42         | 1  Reference  | 1.00  0.72                                                  |
|                        | 3          | 16         | 1.00  0.52-1.90  | 32         | 0.93  0.58-1.49  |                                                      |
|                        | ≥4         | 12         | 1.25  0.56-2.79  | 424        | 1.01  0.60-1.69  |                                                      |
|                        | 1-child increase | 1.19          | 0.94-1.50  |                                                      |                                                      |
| Age at first birth<sup>e</sup>, y | ≤23   | 19         | 1  Reference  | 43         | 1  Reference  | 0.61  0.61                                                  |
|                        | 24-26      | 22         | 0.96  0.51-1.80  | 49         | 1.14  0.75-1.75  |                                                      |
|                        | ≥27        | 14         | 0.97  0.47-1.98  | 24         | 0.83  0.49-1.42  |                                                      |
|                        | 1-y increase | 1.00          | 0.92-1.08  |                                                      |                                                      |
| Breastfeeding<sup>d</sup> | Never     | 9          | 1  Reference  | 10         | 1  Reference  | 0.88                                                  |
|                        | Ever       | 46         | 0.96  0.46-1.97  | 106        | 0.87  0.45-1.68  |                                                      |
| Age at menarche, y     | ≤13        | 18         | 1  Reference  | 6          | 1  Reference  | 0.01  0.31                                                  |
|                        | 14-15      | 32         | 1.32  0.73-2.39  | 53         | 2.88  1.23-6.71  |                                                      |
|                        | ≥16        | 8          | 1.53  0.64-3.66  | 59         | 3.20  1.37-7.48  |                                                      |
|                        | 1-y increase | 1.51          | 1.02-2.22  |                                                      |                                                      |
| Age at menopause<sup>e</sup>, y | ≤48   | 20         | 1  Reference  | 38         | 1  Reference  | 0.89  0.04                                                  |
|                        | 49-51      | 17         | 0.67  0.27-1.65  | 45         | 0.92  0.56-1.50  |                                                      |
|                        | ≥52        | 11         | 2.17  1.03-4.56  | 35         | 0.95  0.58-1.56  |                                                      |
|                        | 1-y increase | 1.08          | 0.98-1.18  |                                                      |                                                      |
| Total fertility span<sup>e</sup>, y | ≤32   | 9          | 1  Reference  | 34         | 1  Reference  | 0.70  0.71                                                  |
|                        | 33-35      | 15         | 1.89  0.79-4.57  | 43         | 1.30  0.81-2.07  |                                                      |
|                        | ≥36        | 25         | 1.95  0.79-4.83  | 41         | 1.12  0.67-1.86  |                                                      |
|                        | 1-y increase | 1.05          | 0.96-1.15  |                                                      |                                                      |
| Menopausal type<sup>e</sup> | Natural  | 41         | 1  Reference  | 111        | 1  Reference  | 0.19                                                  |
|                        | Surgical   | 7          | 1.17  0.52-2.63  | 7          | 0.63  0.29-1.35  |                                                      |
| Exogenous hormone use  | Never use  | 54         | 1  Reference  | 107        | 1  Reference  | 0.19                                                  |
|                        | Ever use   | 4          | 0.43  0.15-1.20  | 11         | 1.02  0.97-1.07  |                                                      |
| Length of menstrual cycle, d | ≤27   | 16         | 1.44  0.76-2.73  | 18         | 1.63  0.93-2.85  | 0.64<sup>f</sup>  0.62                      |
|                        | 28-29      | 23         | 1          | 42         | 1  Reference  |                                                      |

(Continues)
and age at menopause, total ovulatory years and/or natural versus surgical menopause. Although our study observed positive associations between risk of age at menopause, total fertility years and risk of PCM in the complete-case analysis, the association became insignificant in the sensitivity analysis. Taken together, our present and these previous findings suggest that the timing of menarche may play a role in lymphomagenesis, rather than menopause or fertility span.

A novel finding of our study was the association between length of menstrual cycle and risk of lymphoma. Given that a shorter than average menstrual cycle length is associated with decreased levels of luteal estrogens, the possible link between cycle length and risk of lymphoid neoplasm may involve lower cumulative exposure to estrogen. The null result for a dose-response effect of parity on the risk of lymphoid neoplasm was consistent with a recent meta-analysis. In contrast, we also observed a positive association between ever parity and risk of lymphoid neoplasm compared to nulliparity. Nevertheless, the evidence for parous versus nulliparous in this association is scarce, and the experience of childbearing may be an important marker regardless of the number of births. The dramatic increase in estrogen levels during pregnancy leads to a shift from the prevailing cell-mediated immunity (Th1) to antibody-mediated humoral immune (Th2) to protect the fetus. Aggressive development or progression of pregnancy-induced lymphoma may be associated with the development of lymphoid neoplasm. Among women of reproductive age, the prevalence of aggressive lymphoma such as DLBCL is much higher among pregnant than non-pregnant women. The prevalence of extra nodal lymphoma in reproductive organs is also increased during pregnancy. Furthermore, the antibody production-enhancing Th2 immune response during pregnancy may lead women to be susceptible to antibody-mediated autoimmune diseases, which would, in turn, increase subsequent lymphoma risk. Although controversial, 1 group has proposed a potential link between fetal microchimerism during pregnancy and autoimmune disease as an intermediate in the development of lymphoid neoplasm. Nevertheless, given the small number of cases among nulliparous women, we cannot exclude the possibility that our finding was due to chance.

With regard to the timing of pregnancy, 1 cohort study with 2 million women found a reduced risk of NHL with delayed age at first birth, whereas 2 case-control studies reported that early age at first birth was associated with a significantly reduced risk of NHL or null results. The results should, therefore, be considered inconclusive, and age at first birth may not be attributable to the risk of lymphomagenesis.

Regarding the use of exogenous hormones such as oral contraceptives and hormone therapy, previous findings have yielded inconsistent results. The substantial change in exogenous hormone availability and pattern of use over the years prevents comparison of associations with various defined exogenous hormones across studies. For this reason, we were also unable to provide estimations by formulation of exogenous hormones or duration of usage.

| Variable | Category | Cases | HR | 95% CI | P-trendb |
|----------|----------|-------|----|--------|----------|
| Women born after 1941 (n = 22 349) | Regular | 13 | 1.04 | 0.52-2.07 | 0.47 |
| | Irregular | 6 | 0.92 | 0.37-2.29 | 0.85 |
| | Increase | 1.00 | 0.95-1.06 | 0.96 |

TABLE 4 (Continued)
Taken as a whole, our results are unlikely to explain why the incidence of lymphoid neoplasm is higher in men than women. Other proposals made to explain the male predominance in the incidence of lymphoid neoplasm include male sex hormones, and lifestyle-related and occupational-related exposure to radiation and chemical substances, such as smoking, pesticides and benzene. We were unable to assess these factors in this study.

4.1 Strengths and limitations

To our knowledge, this is the first large-scale prospective study of the association between reproductive factors and risk of lymphoid neoplasms. Several advantages of this study warrant mention: its large sample size, high response rate (81%), long duration of follow up and low loss to follow up. Information on many reproductive factors enabled us to assess a variety of potentially relevant exposures. Study subjects consisted of a general population from across Japan, making our findings applicable to the entire Japanese population.

Several limitations should also be mentioned. First, specific data on exogenous hormone use were not available, preventing us from assessing the effects of oral contraceptives and hormone therapy separately. Second, the main findings were obtained from subjects who responded to all relevant questions, which may have introduced a risk of selection bias. However, we aimed to mitigate this issue by using the imputation approach. Third, although we took account of important confounders, we cannot exclude the possibility of other unknown factors. Fourth, the lack of information on possible risk factors may have introduced biased estimations, including infectious status (eg, HBV and HCV) and radiation exposure, even though additional analysis excluded subjects with a history of liver disease which may have been influenced by hepatitis viruses. Finally, because our study subjects were Japanese, the results should be generalized to other populations with care.

In conclusion, we found that late age at menarche, a shorter length of menstrual cycle and ever parity were positively associated with the overall risk of lymphoid neoplasm in the Japanese population. Delayed exposure to various hormones in early life and pregnancy-induced change in immune response may both play a role in the development of lymphoid neoplasm in later life. The various inconsistent findings among studies conducted to date warrant further investigation to determine the mechanisms underlying the effect of reproductive factors in the development of lymphoid neoplasm.

ACKNOWLEDGEMENTS

We are grateful to Dr Tomotaka Ugai for his valuable advice on classification of lymphoid neoplasms. We would like to express our great appreciation to all the staff members for their efforts in conducting the baseline and follow-up surveys as well as the central offices for their cooperation and technical assistance.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTION

MI and NS designed this project; STa conducted the statistical analysis and interpreted the results; STa wrote the manuscript; all authors reviewed, contributed to discussion and approved the final version of the manuscript.

ORCID

Norie Sawada https://orcid.org/0000-0002-9936-1476
Manami Inoue https://orcid.org/0000-0003-1276-2398

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
2. Roman E, Smith AG. Epidemiology of lymphomas. Histopathology. 2011;58:4-14.
3. Costas L, de Sanjose S, Infante-Rivard C. Reproductive factors and non-Hodgkin lymphoma: a systematic review. Crit Rev Oncol Hematol. 2014;92:181-193.
4. Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol. 2010;148:739-753.
5. Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5:e0038.
6. Kato I, Chiebowski RT, Hou L, et al. Menopausal estrogen therapy and non-Hodgkin’s lymphoma: a post-hoc analysis of women’s health initiative randomized clinical trial. Int J Cancer. 2016;138:604-611.
7. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411-423.
8. Costas L, Casabonne D, Benavente Y, et al. Reproductive factors and lymphoid neoplasms in Europe: findings from the Epilymph case-control study. Cancer Causes Control. 2012;23:195-206.
9. Guo P, Huang G, Ren L, Chen Y, Zhou Q. Number of parity and the risk of non-Hodgkin lymphomas: a dose-response meta-analysis of observational studies. Hematology. 2017;22:274-285.
10. Prescott J, Lu Y, Chang ET, et al. Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS ONE. 2009;4:e8135.
11. Chen B, Yang C-Y. Parity, age at first birth, and risk of death from non-Hodgkin’s Lymphoma: a population-based cohort study in Taiwan. Int J Environ Res Public Health. 2015;12:9131.
12. Frisch M, Pedersen BV, Wohlfahrt J, Hjulgrimm H, Biggar RJ. Reproductive patterns and non-Hodgkin lymphoma risk in Danish women and men. Eur J Epidemiol. 2006;21:673-679.
13. Morton LM, Wang SS, Richessa DA, Schatzkin A, Hollenbeck AR, Lacey JV Jr. Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer. 2009;124:2737-2743.
14. Adami HO, Tsaih S, Lambe M, et al. Pregnancy and risk of non-Hodgkin’s lymphoma: a prospective study. Int J Cancer. 1997;70:155-158.
15. La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. *Int J Cancer*. 1993;53:215-219.

16. Kane EV, Roman E, Becker N, et al. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. *Ann Oncol*. 2012;23:2362-2374.

17. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin’s lymphoma in women. *J Clin Oncol*. 2001;19:1381-1387.

18. Cerhan JR, Habermann TM, Vachon CM, et al. Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women’s health study (United States). *Cancer Causes Control*. 2002;13:131-136.

19. Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. *Am J Epidemiol*. 2008;168:278-288.

20. Zhang Y, Holford TR, Leaderer B, et al. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. *Am J Epidemiol*. 2004;160:766-773.

21. Tsuchiya T, Sawada N. The JPHC study: design and some findings on the typical Japanese diet. *Jpn J Clin Oncol*. 2014;44:777-782.

22. GBD 2015 Mortality and Causes of Death Collaborators: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1459-1544.

23. Nagata C, Matsushita Y, Shimizu H. Prevalence of hormone replacement therapy and user’s characteristics: a community survey in Japan. *Maturitas*. 1996;25:201-207.

24. Thiebaut AC, Benichou J. Choice of time-scale in Cox’s model analysis on Hodgkin and non-Hodgkin disease. *Stat Med*. 2004;23:3803-3820.

25. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin’s and Hodgkin’s lymphoma: a meta-analysis of prospective studies. *Eur J Cancer*. 2011;47:2422-2430.

26. Sergentanis TN, Kanavidis P, Michelakos T, Petridou ET. Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease. *Eur J Cancer Prev*. 2013;22:131-150.

27. Kanda J, Matsuo K, Inoue M, et al. Association of alcohol intake with the risk of malignant lymphoma and plasma cell myeloma in Japanese: a population-based cohort study (Japan Public Health Center-based prospective study). *Cancer Epidemiol Biomark Prev*. 2010;19:429-434.

28. Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. *Pathol Int*. 2008;58:174-182.

29. Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. *Inter viviology*. 2011;54:185-195.

30. MacMahon B, Trichopoulos D, Brown J, et al. Age at menarche, urine estrogens and breast cancer risk. *Int J Cancer*. 1982;30:427-431.

31. Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. *Br J Cancer*. 2011;105:709-722.

32. Natland Fagerhaug T, Forso M, Jacobsen GW, Midthjell K, Andersen LF. Ivar Lund Nilsen T: A prospective population-based cohort study of lactation and cardiovascular disease mortality: the HUNT study. *BMC Public Health*. 2013;13:1070.

33. Schwarz EB, Ray RM, Stuebe AM, et al. Duration of lactation and risk factors for maternal cardiovascular disease. *Obstet Gynecol*. 2009;113:974-982.

34. Horowitz NA, Benyamini N, Wohlfart K, Brenner B, Avivi I. Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review. *Lancet Oncol*. 2013;14:e275-e282.

35. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. *Am J Pathol*. 2008;173:600-609.

36. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood*. 2008;111:4029-4038.

37. Ansell P, Simpson J, Lightfoot T, et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter? *Int J Cancer*. 2011;128:460-466.

38. Tavani A, Pagnolato A, La Vecchia C, Franceschi S. A case-control study of reproductive factors and risk of lymphomas and myelomas. *Leuk Res*. 1997;21:885-888.

39. Triguain et al. Dino J, Jørgensen TN. Suppressive effects of androgens on the immune system. *Cell Immunol*. 2015;294:87-94.

40. Schinasio L, Leon M. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. *Int J Environ Res Public Health*. 2014;11:4449.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Tanaka S, Sawada N, Yamaji T, et al. for the JPHC Study Group. Female reproductive factors and risk of lymphoid neoplasm: The Japan Public Health Center-based Prospective Study. *Cancer Sci*. 2019;110:1-1452. [https://doi.org/10.1111/cas.13962]